Sales dismal female Viagra Addyi, why it is far better than the best-selling men's Viagra?

After the female Viagra Addyi international pharmaceutical company acquired by rand (Valeant Pharmaceuticals, VRX), with sales unsatisfactory, it has only a few weeks out of 227 prescriptions. In this little blue Viagra pills respected today, so why such a small pink pill extent sought so low?
Addyi (generic name fluoride legislation serine class) obtained at the end of the third quarter of FDA-approved for the treatment of HSDD, officially listed on October 17. HSDD is that female hypoactive sexual dysfunction, clinical manifestations of long-term frigidity, lack of sexual fantasies, low libido, low sexual involvement, affect their status and marital relationships. Gynecologists Ohio State University Wexner Medical Center, said Jonathan Schaffir, HSDD small patient population. The physicians who participated in the clinical trial Addyi, he said he was exposed to the patient never consulted Addyi.
Addyi as female sexual dysfunction drugs, often and male sexual dysfunction drugs Viagra (Viagra) for comparison. However, the latter in the first week of sale, prescription volume to more than 500,000. Total sales in 2014, male sexual dysfunction drugs Viagra (sildenafil) and Eli Lilly's Cialis (tadalafil, trade name Cialis) is close to $ 4 billion. In addition to the significant differences in sales above Viagra and Addyi is also a great difference in the mechanism of action and onset time. Viagra's role is to improve sexual performance, and Addyi for improving libido. Viagra can be taken as needed, immediate action; and Addyi need to be taken daily, and for taking four weeks after the order has improved in the "exotic" on.
Before marketing authorization, Addyi repeatedly been rejected FDA. When early in 2010, Addyi also belong Boehringer Inge John, it was rejected once. Sprout took over the company in 2011, Addyi listing application by the FDA in 2013 also returned. 2015, FDA only through the listing application of the drug. However, serious side effects of the drug are also "black box warning" appears in the manual. Addyi may cause severe hypotension, or even shock the patient. Alcohol can increase the blood pressure decrease. Apart from a small number of patients and severe side effects than, the price is too high it is one of the factors affecting sales.
Addyi spending about $ 800 a month. After the acquisition of Sprout company, Valeant companies to improve the practice of drug prices blamed. Some insurers frankly, because the price is too high, they are not listed in the Addyi within the insurance coverage, or just include it in a higher amount of the policy. Sprout told Bloomberg that a patient assisted project is expected to start the company plans to price controls will Addyi about $ 200 a month.
After Addyi approved for marketing, Sprout says Sprout certified pharmacists need to be issued after the drug and conduct patient education, tell the patient to use the drug risks and side effects, especially severe hypotension when sharing with alcohol. So far, Sprout has been issued for this drug may 5600 physicians, gynecologists and about 1% general practitioners were trained.
After Addyi obtain FDA clearance to market, Valeant company through the acquisition of Sprout will Addyi bag. When announcing the transaction, Valeant current CEO Michael Pearson said: "This acquisition, so that Valeant has a unique and important female drugs." Sprout CEO Cindy Whitehead said, Valeant has a mature sales force, women around the world have the ability to have the opportunity to spend Addyi.